TrialJournal for immunotherapy of cancer2021

CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.

Rachel E Sanborn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.